ISSCR News
The ISSCR Recognizes Outstanding Poster Award Winners at the ISSCR 2026 Annual Meeting in Montreal
The International Society for Stem Cell Research (ISSCR) has recognized five outstanding scientists with Poster Awards at the ISSCR 2026 Annual Meeting, honoring innovative research spanning developmental biology, disease modeling, regenerative medicine, and functional genomics.
Selected from more than 1,300 scientific posters presented during the meeting, the awards recognize exceptional research and scientific communication. Winning posters were evaluated by senior stem cell scientists attending the meeting, underscoring the rigor and peer recognition behind the awards.
New First-in-Human Study Presented at ISSCR 2026 Explores Immune-Engineered Cell Therapy Approach for Type 1 Diabetes
Research evaluates whether hypoimmune cell engineering can help transplanted insulin-producing cells survive without chronic immunosuppression
New research presented today at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells can survive and function without chronic immunosuppression.
The study addresses one of the field’s central challenges: overcoming immune rejection, which has limited the broader use of islet and stem cell-based replacement therapies for type 1 diabetes.
Stem Cell Strategy for Chronic Spinal Cord Injury Advances
New preclinical findings and updated clinical trial plans presented today at ISSCR 2026 highlight a tailored stem cell approach designed to overcome the long-standing barriers of chronic paralysis
New research presented today at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting highlights a significant step toward developing a stem cell-based treatment for chronic spinal cord injury (SCI), a condition for which no effective restorative therapy currently exists.
First Clinical Trial of Pluripotent Stem Cell-Derived Neural Stem Cells for Huntington’s Disease Highlighted at ISSCR 2026
Phase 1b/2a study marks an important milestone in the development of regenerative medicine approaches for Huntington's disease
An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington’s disease was presented today at the ISSCR 2026 Annual Meeting. The Phase 1b/2a REGEN4HD study represents a significant translational milestone following years of preclinical research, pivotal safety studies, regulatory engagement, and clinical trial development.
New Clinical Data Presented at ISSCR 2026 Demonstrate One-Year Survival of Stem Cell-Derived Neural Progenitor Cells in Patients with Retinitis Pigmentosa
New, previously unpublished clinical data was presented today at ISSCR 2026 demonstrating that transplanted human neural progenitor cells survived for at least one year following subretinal transplantation in patients with retinitis pigmentosa (RP), while maintaining a favorable safety profile.
Retinitis pigmentosa is a group of inherited retinal diseases that progressively causes vision loss currently has no treatment for most patients. Because thousands of different genetic mutations can cause the disease, developing mutation-specific gene therapies remains challenging. Cell-based therapies offer the potential for a gene-agnostic approach that could benefit a broader population of patients.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .